 |
|
Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial
Cheolmin Shin, Young-Hoon Ko, Se-Hoon Shim, Ji Sun Kim, Kyoung-Sae Na, Sang-Woo Hahn, Seung-Hwan Lee
Psychiatry Investig. 2020;17(8):796-803. Published online 2020 Aug 6 DOI: https://doi.org/10.30773/pi.2020.0017
|
|
Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis
Yue Du, Qing Li, Yikai Dou, Min Wang, Yu Wang, Yushun Yan, Huanhuan Fan, Xiao Yang, Xiaohong Ma
Heliyon.2024; 10(7): e28918. CrossRef Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research
Michael J. Colwell, Hosana Tagomori, Sarah Chapman, Amy L. Gillespie, Philip J. Cowen, Catherine J. Harmer, Susannah E. Murphy
Translational Psychiatry.2022;[Epub] CrossRef Galanin(1-15) Potentiates the Antidepressant-like Effects Induced by Escitalopram in a Rat Model of Depression
Laura García-Durán, Antonio Flores-Burgess, Noelia Cantero-García, Araceli Puigcerver, José Ángel Narváez, Kjell Fuxe, Luis Santín, Carmelo Millón, Zaida Díaz-Cabiale
International Journal of Molecular Sciences.2021; 22(19): 10848. CrossRef
|